Eris Lifesciences: Rating Boost Despite Missed Estimates

  Published 1 year ago

Despite falling short of Bloomberg's projections, Eris Lifesciences saw a stock boost following Macquarie’s reaffirmed ‘Outperform’ rating and ₹1680 target price. The company demonstrated substantial YoY growth in profit, EBITDA, and revenue.

  • Macquarie maintains an ‘Outperform’ rating.
  • Revenue grew 28% year over year.
  • Profit increased 32% YoY.

You might like these

Mahindra SUV Sales Jump 20% in July

India Forex Reserves Hit $703bn in One Week

Jindal Mobilitric Unveils High-Range EV, Awaits Approval

India's Strong 2025 Growth Outlook

Nike Stock Jumps on Amazon Return, Price Hike

Endurance Boosts ABS Capacity with ₹135.6 Cr Investment

Cohance FY26 Growth: Niche Tech, CDMO, Chemicals

News that matters the most ⚡